Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.

This report describes a woman aged 22 years with unresectable ALK-negative IMT. Next-generation sequencing revealed a TFG-ROS1 fusion, and she had a partial response to the ROS1 inhibitor ceritinib. This report provides the first published demonstration of a patient with IMT with ROS1 fusion successfully treated using ceritinib. Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials. PMID: 31805529 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Related Links:

ashi Soft tissue sarcoma (STS) is a rare component of malignant diseases. STS includes various histological subtypes, and there are some important differences among the different histological subtypes regarding the mutation profile and sensitivity to antitumor agents. Many clinical trials of STS incorporating many different histological subtypes in various populations have been conducted; it is difficult to compare the findings and make conclusions about clinical efficacy. Targeted therapies focusing on specific histological subtypes and precision therapy focusing on the specific genetic mutation(s) of each STS patient...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
(University of Texas M. D. Anderson Cancer Center) Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(INSERM (Institut national de la sant é et de la recherche m é dicale)) How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer? An international team led by Wolf Herv é Fridman with researchers from Inserm, Sorbonne Universit é and Universit é de Paris, has shown that B cells also play a major role in predicting of patient's response to immunotherapy. Their findings, to be published in Nature, pave the way for the personalization of treatments for patients with soft tissue sarcomas.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
ConclusionsLung autotransplantation following ex vivo bench surgery was found to be technically feasible for various lung diseases, showing a favorable early post-transplant outcome.
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
el Haendler Eheim Stresemann Inhibiting the interaction of menin with the histone methyltransferase MLL1 (KMT2A) has recently emerged as a novel therapeutic strategy. Beneficial therapeutic effects have been postulated in leukemia, prostate, breast, liver and in synovial sarcoma models. In those indications, MLL1 recruitment by menin was described to critically regulate the expression of disease associated genes. However, most findings so far rely on single study reports. Here we independently evaluated the pathogenic functions of the menin-MLL interaction in a large set of different cancer models with a poten...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conditions:   Cervical Cancer;   Ovarian Tumor;   Endometrial Carcinoma;   Uterine Myomatosis;   Adenomyosis;   Ovarian Cyst Benign;   Ovarian Cyst Malignant;   Endometriosis;   Uterine Sarcoma Intervention:   Other: Intravenous ICG and Real-Time Near-infrared Imaging Sponsors:   Chen Chunlin;   Chinese Academy of Sciences;   Beijing Key Laboratory of Molecular Imaging Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
a Renata Veselska Serial xenotransplantation of sorted cancer cells in immunodeficient mice remains the most complex test of cancer stem cell (CSC) phenotype. However, we have demonstrated in various sarcomas that putative CSC surface markers fail to identify CSCs, thereby impeding the isolation of CSCs for subsequent analyses. Here, we utilized serial xenotransplantation of unsorted rhabdomyosarcoma cells in NOD/SCID gamma (NSG) mice as a proof-of-principle platform to investigate the molecular signature of CSCs. Indeed, serial xenotransplantation steadily enriched for rhabdomyosarcoma stem-like cells characterized ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractBackgroundOlder age is associated with worse outcome in synovial sarcoma (SS) patients. Differences in disease presentation among distinct age groups, however, are currently unknown.MethodsSS patients    10 cm was higher (13%, 21%, 31%;p = 0.005657) whereas conversely, the proportion of small tumors 
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 24 December 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Jessica L. Mester, Sarah A. Jackson, Kristen Postula, Amy Stettner, Sheila Solomon, Jeffrey Bissonnette, Patricia D. Murphy, Rachel T. Klein, Kathleen S. HruskaHeterozygous (HET) TP53 pathogenic variants (PVs) are associated with Li-Fraumeni syndrome (LFS), a dominantly inherited condition causing high risk for sarcoma, breast, and other cancers. Recent reports described patients without features of LFS and apparently HET TP53 PVs in blood cells but not fibroblasts (FBs), suggesting the variant occurred sporadically du...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Authors: Krumbholz M, Agaimy A, Stoehr R, Burger M, Wach S, Taubert H, Wullich B, Hartmann A, Metzler M Abstract There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially available single nucleotide mutation assays for quantification of ctDNA are insufficient for therapy assessment in this disease. However, prostate cancer shares some similarity with translocation-affected mesench...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Sarcomas | Study